Effects of a novel cyclic RGD peptidomimetic on cell proliferation, migration and angiogenic activity in human endothelial cells

Vascular Cell

Volumn 6, Issue 1, 2014, Pages

  Fanelli, Roberto ^a   Schembri, Laura ^a   Piarulli, Umberto ^a   Pinoli, Monica ^a   Rasini, Emanuela ^a   Paolillo, Mayra ^b   Galiazzo, Marisa Carlotta ^b   Cosentino, Marco ^a   Marino, Franca ^a  

^a UNIVERSITY OF INSUBRIA   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

Author keywords

Angiogenesis; Human umbilical vein endothelial cells; Integrins; Interleukin 8; RGD peptidomimetics

Indexed keywords

ALPHAVBETA5 INTEGRIN; ARGINYLGLYCYLASPARTIC ACID; BROXURIDINE; CYCLIC RGD PEPTIDOMIMETIC AGENT; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR; INTERLEUKIN 8; LIPOCORTIN 5; MESSENGER RNA; PEPTIDOMIMETIC AGENT; PIPERAZINEDIONE; PROPIDIUM IODIDE; PROTEIN KINASE B; SOMATOMEDIN C; UNCLASSIFIED DRUG; VASCULOTROPIN; VITRONECTIN RECEPTOR;

ANGIOGENESIS; ANGIOGENESIS ASSAY; ANTIANGIOGENIC ACTIVITY; ARTICLE; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CELL VIABILITY ASSAY; CONTROLLED STUDY; CYTOTOXICITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMAGE ANALYSIS; MICROSCOPY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; UMBILICAL VEIN ENDOTHELIAL CELL; WESTERN BLOTTING;

EID: 84901689472     PISSN: None     EISSN: 2045824X     Source Type: Journal    
DOI: 10.1186/2045-824X-6-11     Document Type: Article

References (32)

1. Mechanisms of angiogenesis and arteriogenesis. Carmeliet P, Nat Med 2000 6 389 395 10.1038/74651 10742145 (Pubitemid 30208155)
2. Peptide-based molecules in angiogenesis. D'Andrea LD, Del Gatto A, Pedone C, Benedetti E, Chem Biol Drug Des 2006 67 115 126 10.1111/j.1747-0285.2006. 00356.x 16492159 (Pubitemid 43881373)
3. IL-8 Directly enhanced endothelial cell survival, proliferation, and matrix metalloproteinases production and regulated angiogenesis. Li A, Dubey S, Varney ML, Bhavana J, J Immunol 2003 170 3369 3376 10.4049/jimmunol.170.6.3369 12626597 (Pubitemid 36302216)
4. Signal transduction by cell adhesion receptor and the cytoskeleton: function of integrins, cadherins, selectins, and immunoglobulin-superfamily members. Juliano RL, Annu Rev Pharmacol Toxicol 2002 42 283 323 10.1146/annurev.pharmtox.42.090401.151133 11807174 (Pubitemid 34160528)
5. Integrins in angiogenesis: multitalented molecules in a balancing act. Hodivala-Dilke KM, Reynolds AR, Reynolds LE, Cell Tissue Res 2003 314 131 144 10.1007/s00441-003-0774-5 13680353 (Pubitemid 37409919)
6. Ligand binding to integrins. Plow EF, Haas TA, Zhang L, Loftus J, Smith JW, J Biol Chem 2000 275 21785 21788 10.1074/jbc.R000003200 10801897 (Pubitemid 30621742)
7. Crystal structure of the extracellular segment of integrin alpha V beta 3 in complex with an Arg-Gly-Asp ligand. Xiong JP, Stehle T, Zhang R, Joachimiak A, Frech M, Goodman SL, Arnaout MA, Science 2002 296 151 155 10.1126/science.1069040 11884718 (Pubitemid 34280076)
8. Small molecule integrin antagonists in cancer therapy. Paolillo M, Russo MA, Serra M, Colombo L, Schinelli S, Mini-Rev Med Chem 2009 9 1439 1446 10.2174/138955709789957404
9. Ligands for mapping alphavbeta3-integrin expression in vivo. Schottelius M, Laufer B, Kessler H, Wester HJ, Acc Chem Res 2009 42 7 969 980 10.1021/ar800243b 19489579
10. Cilengitide: the first anti-angiogenic small molecule drug candidate. Design, synthesis and clinical evaluation. Mas-Moruno C, Rechenmacher F, Kessler H, Anti-Cancer Agents Med Chem 2010 10 753 768 10.2174/187152010794728639 21269250
11. Combination therapy of cilengitide with belotecan against experimental glioblastoma. Kim YH, Lee JK, Kim B, DeWitt JP, Lee JE, Han JH, Kim SK, Oh CW, Kim CY, Int J Cancer 2013 133 749 756 10.1002/ijc.28058 23354807
12. First experience of 18 F-alfatide in lung cancer patients using a new lyophilized kit for rapid radiofluorination. Wan W, Guo N, Pan D, Yu C, Weng Y, Luo S, Ding H, Xu Y, Wang L, Lang L, Xie Q, Yang M, Chen X, J Nucl Med 2013 54 691 698 10.2967/jnumed.112.113563 23554506
13. Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors. Reynolds AR, Hart IR, Watson AR, Welti JC, Silva RG, Robinson SD, Da Violante G, Gourlaouen M, Salih M, Jones MC, Jones DT, Saunders G, Kostourou V, Perron-Sierra F,JC, Tucker GC, Hodivala-Dilke KM, Nat Med 2009 15 392 400 10.1038/nm.1941 19305413
14. 3 integrin. Papo N, Silverman AP, Lahti JL, Cochran JR, Proc Natl Acad Sci U S A 2011 108 14067 14072 10.1073/pnas.1016635108 21825147
15. Cyclic RGD-peptidomimetics containing bifunctional diketopiperazine scaffolds as new potent integrin ligands. Ressurreiçao ASM, Vidu A, Civera M, Belvisi L, Potenza D, Manzoni L, Ongeri S, Gennari C, Piarulli U, Chem Eur J 2009 15 12184 12188 10.1002/chem.200902398 19830748
16. Cyclic RGD-peptidomimetics containing bifunctional diketopiperazine scaffolds as new potent integrin ligands. Marchini M, Mingozzi M, Colombo R, Guzzetti I, Belvisi L, Vasile F, Potenza D, Piarulli U, Arosio D, Gennari C, Chem Eur J 2012 18 6195 6207 10.1002/chem.201200457 22517378
17. Role of Akt signaling in vascular homeostasis and angiogenesis. Shiojima I, Walsh K, Circ Res 2002 90 1243 1250 10.1161/01.RES.0000022200.71892.9F 12089061 (Pubitemid 34787405)
18. A small-molecule RDG-integrin antagonist inhibits cell adhesion, cell migration and induces anoikis in glioblastoma cells. Russo MA, Paolillo M, Sanchez-Hernandes Y, Curti D, Ciusani E, Serra M, Colombo L, Schinelli S, International J of Oncology 2013 42 83 92
19. Toll-like receptor 2 in promoting angiogenesis after acute ischemic injury. Xu Y, Zhou Y, Lin H, Hu H, Wang Y, Xu G, Int J Mol Med Mar 2013 31 555 560
20. Cell-matrix adhesion in vascular development. Hynes RO, J Thromb Haemost 2007 1 32 40 (Pubitemid 46964284)
21. Integrin alpha v beta 3 as a therapeutic target for blocking tumor-induced angiogenesis. Kumar CC, Curr Drug Targets 2003 4 123 131 10.2174/1389450033346830 12558065 (Pubitemid 36553584)
22. Expression of integrins and adhesive properties of human endothelial cell line EA.hy 926. Baranska P, Jerczynska H, Pawlowska Z, Koziolkiewicz W, Cierniewski CS, Cancer Genomics Proteomics 2005 2 265 270
23. Cilengitide induces autophagy-mediated cell death in glioma cells. Lomonaco SL, Finniss S, Xiang CL, Lee HK, Jiang W, Lemke N, Rempel SA, Mikkelsen T, Brodie C, Neuro Oncol 2011 13 857 865 10.1093/neuonc/nor073 21788343
24. Plaque neovascularization: defense mechanisms, betrayal, or a war in progress. Moreno PR, Purushothaman M, Purushothaman KR, Ann NY Acad Sci 2012 1254 7 17 10.1111/j.1749-6632.2012.06497.x 22548565
25. 3. Colombo R, Mingozzi M, Belvisi L, Arosio D, Piarulli U, Carenini N, Perego P, Zaffaroni N, De Cesare M, Castiglioni V, Scanziani E, Gennari C, J Med Chem 2012 55 10460 10474 10.1021/jm301058f 23140358
26. Integrin and growth factor receptor crosstalk. Eliceiri BP, Circ Res 2001 89 1104 1110 10.1161/hh2401.101084 11739274 (Pubitemid 34627867)
27. An Inhibitor of a Cell Adhesion Receptor Stimulates Cell Migration. Shabbir SH, Eisenberg JL, Mrksich M, Angew Chem Int Ed 2010 49 7706 7709 10.1002/anie.201002699
28. The interleukin-8 pathway in cancer. Waugh DJJ, Wilson C, Clin Cancer Res 2008 14 6735 6741 10.1158/1078-0432.CCR-07-4843 18980965
29. Molecular pathways: fibroblast growth factor signaling: a new therapeutic opportunity in cancer. Brooks AN, Kilgour E, Smith PD, Clin Cancer Res 2012 18 1855 1862 10.1158/1078-0432.CCR-11-0699 22388515
30. Targeting the vascular endothelial growth factor in hematologic malignancies. Paesler J, Gehrke I, Poll-Wolbeck SJ, Kreuzer KA, Eur J Haematol 2012 89 373 384 10.1111/ejh.12009 22928557
31. Active antitumor immunity elicited by vaccine based on recombinant form of epidermal growth factor receptor. Hu B, Wei YQ, Tian L, Zhao X, Lu Y, Wu Y, Yao B, Liu JY, Niu T, Wen YJ, He QM, Su JM, Huang MJ, Lou YY, Luo Y, Kan B, J Immunother 2005 28 236 244 10.1097/01.cji.0000161394.11831.3f 15838380 (Pubitemid 40593989)
32. Angiogenesis in atherosclerosis: gathering evidence beyond speculation. Moulton KS, Karen S, Curr Opin Lipidol 2006 17 548 555 10.1097/01.mol. 0000245261.71129.f0 16960504 (Pubitemid 44372686)